Stockreport

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Bilia...

Jazz Pharmaceuticals plc - Ordinary Shares  (JAZZ) 
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com
PDF Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independe [Read more]